Related Experiment Video
Updated: Oct 9, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Spraying houses in the Peruvian Andes with lambda-cyhalothrin protects residents against cutaneous leishmaniasis
C R Davies1, E A Llanos-Cuentas, P Campos
1Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. c.davies@lshtm.ac.uk
Abstract:
A household vector control trial was carried out in the Peruvian Andes to measure the effect of spraying inside walls and ceilings with lambda-cyhalothrin on the risk for residents of cutaneous leishmaniasis caused by Leishmania peruviana. The mortality rates of Lutzomyia verrucarum measured with WHO contact bioassay cones set on adobe walls characteristic of the endemic region indicated an LD95 for lambda-cyhalothrin of about 20 mg/m2, and no reduction in effectiveness for at least 6 months on indoor adobe walls sprayed with 25 mg/m2. A random selection of 112 houses were sprayed (starting in 1992/93) at 6-monthly intervals with a mean dose of 34 mg/m2, leaving 154 control houses (with closely matched pre-intervention measurements of incidence and sandfly abundance). Comparisons of pre- and post-intervention sandfly indoor abundance, measured at regular intervals for up to 2 years using CDC light traps, in 22 sprayed and 21 control houses demonstrated that spraying significantly reduced the indoor abundance of Lu. verrucarum by an average of 78% and of Lu. (Helcocyrtomyia) peruensis by 83%. Spraying was also associated with a significant reduction of 77% in the proportion of bloodfed sandflies collected in light traps. The proportion of susceptible householders acquiring leishmaniasis during the trial was significantly reduced by 54% as a result of spraying. The observed impact of spraying was greatest, 81% (95% confidence intervals 20-95%), when the cases detected during the first 6 months after the intervention were excluded from the analysis, suggesting a significant pre-patent period.
More Related Videos
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
Anthelminthic Agents